pIRS2-phosphopeptide

The pIRS2-phosphopeptide is an investigational cancer vaccine consisting of a phosphorylated peptide derived from the insulin receptor substrate 2 protein (specifically the HLA-A*0201-restricted sequence pIRS2 1097-1105). Developed by Craig L. Slingluff, Jr. and researchers at the University of Virginia, this vaccine targets a unique class of tumor-associated neoantigens created by post-translational phosphorylation. These phosphopeptides are presented by MHC class I molecules on the surface of various cancer cells, including melanoma, breast, and colorectal cancers, but are generally absent or present at much lower levels on normal tissues. The vaccine is designed to stimulate a specific CD8+ T-cell immune response against tumor cells expressing this target. In clinical settings, such as the Mel59 trial, it is often administered in combination with other phosphopeptides (like pBCAR3) and adjuvants such as PolyICLC and Montanide ISA-51 to enhance immunogenicity.

Other names

pIRS2 phosphopeptide vaccinepIRS-2 phosphopeptide vaccinepIRS 2 phosphopeptide vaccineIRS2 phosphopeptideIRS-2 phosphopeptideIRS 2 phosphopeptidePhosphorylated insulin receptor substrate 2 peptide